Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
New Targeted Radiopharmaceuticals and Techniques for Nuclear Imaging of Inflammation
share announcement

New Targeted Radiopharmaceuticals and Techniques for Nuclear Imaging of Inflammation

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".

Deadline for manuscript submissions: closed (21 March 2021) | Viewed by 5740

Special Issue Editors

Prof. Dr. Anne Roivainen

E-Mail Website
Guest Editor
1. Turku PET Centre, University of Turku, Turku, Finland
2. Turku Center for Disease Modeling, University of Turku, Turku, Finland
3. Turku PET Centre, Turku University Hospital, Turku, Finland
Interests: medical biochemistry; radiopharmaceuticals; molecular imaging; imaging agents; inflammation; infection; cancer; positron emission tomography
Special Issues, Collections and Topics in MDPI journals
Dr. Xiang-Guo Li

E-Mail Website
Guest Editor
Turku PET Centre, University of Turku and Åbo Akademi University, FI-20521 Turku, Finland
Interests: radiopharmaceuticals; radiochemistry; positron emission tomography; medicinal chemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammation is involved in disease progressing and healing, thus having a significant role in diagnosis and therapy. Upon inflammation, a number of biomarkers are upregulated, which provides opportunities for early diagnosis with, for example, nuclear medicine approaches. To read out the biomarker profile in an inflammatory disease, different types of radiolabeled probes and imaging techniques are continuously needed. The aim of this Special Issue in Biomolecules is to promote the dissemination of fresh research results on inflammation imaging. More specifically, this Special Issue is dedicated to radiopharmaceuticals and imaging techniques for inflammatory diseases with positron emission tomography and single-photon emission computed tomography, in the context of preclinical and clinical evaluation of new radiopharmaceuticals. Studies can be from basic research in new radiopharmaceutical development, as well as new imaging methods and applications with existing radiopharmaceuticals in preclinical and clinical settings. It is equally valuable to receive reports on clinical cases with extraordinarily good imaging performances, even though neither the imaging probes nor the techniques are new.

Prof. Dr. Anne Roivainen
Dr. Xiang-Guo Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Inflammation
  • Nuclear medicine
  • Nuclear pharmacy
  • Positron emission tomography
  • Single-photon emission computed tomography
  • Radiopharmaceuticals
  • Imaging techniques
  • Preclinical PET imaging
  • Clinical PET imaging

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3612 KiB  
Article
In Vitro and In Vivo Evaluation of 99mTc-Polymyxin B for Specific Targeting of Gram-Bacteria
by Sveva Auletta, Filippo Galli, Michela Varani, Giuseppe Campagna, Martina Conserva, Daniela Martinelli, Iolanda Santino and Alberto Signore
Biomolecules 2021, 11(2), 232; https://doi.org/10.3390/biom11020232 - 5 Feb 2021
Cited by 6 | Viewed by 2270
Abstract
Background: Infectious diseases are one of the main causes of morbidity and mortality worldwide. Nuclear molecular imaging would be of great help to non-invasively discriminate between septic and sterile inflammation through available radiopharmaceuticals, as none is currently available for clinical practice. Here, we [...] Read more.
Background: Infectious diseases are one of the main causes of morbidity and mortality worldwide. Nuclear molecular imaging would be of great help to non-invasively discriminate between septic and sterile inflammation through available radiopharmaceuticals, as none is currently available for clinical practice. Here, we describe the radiolabeling procedure and in vitro and in vivo studies of 99mTc-polymyxin B sulfate (PMB) as a new single photon emission imaging agent for the characterization of infections due to Gram-negative bacteria. Results: Labeling efficiency was 97 ± 2% with an average molar activity of 29.5 ± 0.6 MBq/nmol. The product was highly stable in saline and serum up to 6 h. In vitro binding assay showed significant displaceable binding to Gram-negative bacteria but not to Gram-positive controls. In mice, 99mTc-HYNIC-PMB was mainly taken up by liver and kidneys. Targeting studies confirmed the specificity of 99mTc-HYNIC-PMB obtained in vitro, showing significantly higher T/B ratios for Gram-negative bacteria than Gram-positive controls. Conclusions: In vitro and in vivo results suggest that 99mTc-HYNIC-PMB has a potential for in vivo identification of Gram-negative bacteria in patients with infections of unknown etiology. However, further investigations are needed to deeply understand the mechanism of action and behavior of 99mTc-HYNIC-PMB in other animal models and in humans. Full article
(This article belongs to the Special Issue New Targeted Radiopharmaceuticals and Techniques for Nuclear Imaging of Inflammation)
►▼ Show Figures

Figure 1

12 pages, 2062 KiB  
Article
[68Ga]Ga-Pentixafor for PET Imaging of Vascular Expression of CXCR-4 as a Marker of Arterial Inflammation in HIV-Infected Patients: A Comparison with 18F[FDG] PET Imaging
by Ismaheel O. Lawal, Gbenga O. Popoola, Johncy Mahapane, Jens Kaufmann, Cindy Davis, Honest Ndlovu, Letjie C. Maserumule, Kgomotso M. G. Mokoala, Hakim Bouterfa, Hans-Jürgen Wester, Jan Rijn Zeevaart and Mike M. Sathekge
Biomolecules 2020, 10(12), 1629; https://doi.org/10.3390/biom10121629 - 3 Dec 2020
Cited by 10 | Viewed by 2699
Abstract
People living with human immunodeficiency virus (PLHIV) have excess risk of atherosclerotic cardiovascular disease (ASCVD). Arterial inflammation is the hallmark of atherogenesis and its complications. In this study we aimed to perform a head-to-head comparison of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([ [...] Read more.
People living with human immunodeficiency virus (PLHIV) have excess risk of atherosclerotic cardiovascular disease (ASCVD). Arterial inflammation is the hallmark of atherogenesis and its complications. In this study we aimed to perform a head-to-head comparison of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) and Gallium-68 pentixafor positron emission tomography/computed tomography [68Ga]Ga-pentixafor PET/CT for quantification of arterial inflammation in PLHIV. We prospectively recruited human immunodeficiency virus (HIV)-infected patients to undergo [18F]FDG PET/CT and [68Ga]Ga-pentixafor PET/CT within two weeks of each other. We quantified the levels of arterial tracer uptake on both scans using maximum standardized uptake value (SUVmax) and target–background ratio. We used Bland and Altman plots to measure the level of agreement between tracer quantification parameters obtained on both scans. A total of 12 patients were included with a mean age of 44.67 ± 7.62 years. The mean duration of HIV infection and mean CD+ T-cell count of the study population were 71.08 ± 37 months and 522.17 ± 260.33 cells/µL, respectively. We found a high level of agreement in the quantification variables obtained using [18F]FDG PET and [68Ga]Ga-pentixafor PET. There is a good level of agreement in the arterial tracer quantification variables obtained using [18F]FDG PET/CT and [68Ga]Ga-pentixafor PET/CT in PLHIV. This suggests that [68Ga]Ga-pentixafor may be applied in the place of [18F]FDG PET/CT for the quantification of arterial inflammation. Full article
(This article belongs to the Special Issue New Targeted Radiopharmaceuticals and Techniques for Nuclear Imaging of Inflammation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop